



Advances in SARS-CoV-2 Infection

Guest Editor:

Prof. Dr. Carlo Contini

Infectious and Tropical Diseases,
University of Ferrara, Ferrara,
Italy

Deadline for manuscript
submissions:

closed (20 December 2022)

Message from the Guest Editor

More than a year has passed since the new coronavirus SARS-CoV-2 entered our lives, causing worldwide grief and economic devastation in the form of COVID-19. COVID-19 is multifaceted, with a variety of clinical expressions from mild or moderate symptoms that generally heal without the need for any treatment, to more severe and devastating effects.

In the therapeutic field, there is still no definitive curative drug. However, several currently available vaccines were manufactured in just 18 months. The positive effects of the vaccination campaign are being seen in many parts of the world. However, the disappearance of this new infection is still far from being a reality, as it is also threatened by the presence of numerous viral variants.

The purpose of this Special Issue is to focus on the main biological, epidemiological and clinical aspects of the virus, but above all on therapeutic and preventive aspects in the light of the newly acquired knowledge.





an Open Access Journal by MDPI

Editor-in-Chief

Dr. Nico Jehmlich

Department of Molecular
Toxicology, UFZ-Helmholtz
Centre for Environmental
Research, 04318 Leipzig,
Germany

Message from the Editor-in-Chief

"Microorganism" merges the idea of the very small with the idea of the evolving reproducing organism is a unifying principle for the discipline of microbiology. Our journal recognizes the broadly diverse yet connected nature of microorganisms and provides an advanced publishing forum for original articles from scientists involved in high-quality basic and applied research on any prokaryotic or eukaryotic microorganism, and for research on the ecology, genomics and evolution of microbial communities as well as that exploring cultured microorganisms in the laboratory.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, PubAg, CAPlus / SciFinder, AGRIS, and other databases.

Journal Rank: JCR - Q2 (Microbiology) / CiteScore - Q1 (Microbiology (medical))

Contact Us

Microorganisms Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/microorganisms
microorganisms@mdpi.com
X@Micro_MDPI